Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 12, 2015, Pages 2839-2848

  Rudenko, Larisa ^a   Naykhin, Anatoly ^a   Donina, Svetlana ^a   Korenkov, Daniil ^a   Petukhova, Galina ^a   Isakova Sivak, Irina ^a   Losev, Igor ^a   Stukova, Marina ^b   Erofeeva, Mariana ^b   Nikiforova, Alexandra ^c   Power, Maureen ^d   Flores, Jorge ^a,d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

^b Research Institute of Influenza   (Russian Federation)

^c Department of Preclinical Trials Microge ^*  (Russian Federation)

^d PATH   (United States)

Author keywords

Clinical trial; H5 avian influenza viruses; Inactivated influenza vaccine; Live attenuated influenza vaccine; Memory immune response; Prime boost strategy; Safety

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION; HUMAN CELL; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOGENICITY; INFLUENZA; INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H5N2); MALE; NONHUMAN; OPTICAL DENSITY; SEROCONVERSION; ANTIBODY PRODUCTION; B LYMPHOCYTE; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; SECONDARY IMMUNIZATION; VACCINATION;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA VACCINES; MALE; VACCINATION; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84961821455     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1069931     Document Type: Article

References (40)

1. WHO, WHO global influenza preparedness plan. WHO/CDS/CSR/GIP/2005.5 http://www.who.int/csr/resources/publications/influenza/en/WHO_CDS_CSR_GIP_2005_5.pdf. 2005
2. Anonymous, Development of a Clinical Trial Plan for Pandemic Influenza Vaccines. Department of Health and Human Services. National Institute of Allergy and Infection Diseases. September 22-23, 2003, Bethesda, Maryland. Meeting Summary. http://www.niaid.nih. gov/about/organization/dmid/Documents/pansum mary.pdf.2003
3. WHO, Tables on clinical evaluation of influenza vaccines. http://www.who.int/immunization/diseases/influ.enza/clinical_evaluation_tables/en/. WHO, Geneva, Switzerland 2014.
4. Rudenko L, Isakova-Sivak I. Pandemic Preparedness with Live Attenuated Influenza Vaccines Based on A/Leningrad/134/17/57 (H2N2) Master Donor Virus. Expert Review of Vaccines, 2015. 14(3): p:395-412; PMID 25555687; http://dx.doi.org/10.1586/14760584.2015.979159
5. Coelingh KL, Luke CJ, Jin H, Talaat KR. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev Vaccines 2014. 13 (7): p:855-71; PMID 24867587; http://dx.doi.org/10.1586/14760584.2014.922417
6. Isakova-Sivak I, Stukova M, Erofeeva M, Naykhin A, Donina S, Petukhova G, Kuznetsova V, Kiseleva I, Smolonogina T, Dubrovina I, et al. H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Hum Vaccin Immunother, 2015. 11(4): p:970-82; PMID 25831405; http://dx.doi.org/10.1080/21645515.2015.1010859
7. Baz M, Luke CJ, Cheng X, Jin H, Subbarao K. H5N1 vaccines in humans. Virus Res, 2013; 178(1):78-98; PMID 23726847
8. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis, 2008.198(5): p:635-41; PMID 18694338; http://dx.doi.org/10.1086/590916
9. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/ Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003. 21(15): p:1687-93; PMID 12639491; http://dx.doi.org/10.1016/S0264-410X(02)00632-1
10. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis, 2011. 11(12): p:916-24; PMID 21975270; http://dx.doi.org/10.1016/S1473-3099(11)70240-7
11. Ledgerwoo JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013. 208(3): p:418-22; PMID 23633407; http://dx.doi.org/10.1093/infdis/jit180
12. WHO, Global pandemic influenza action plan to increase vaccine supply. Geneva, Belgium. WHO/IVB/06.13. WHO/ODS/EPR/GIP/2006.1 http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.13_eng.pdf, 2006
13. Powell TJ, Strutt T, Reome J, Hollenbaugh JA, Roberts AD, Woodland DL, Swain SL, Dutton RW. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol 2007. 178(2): p:1030-8; PMID 17202366; http://dx.doi.org/10.4049/jimmunol.178.2.1030
14. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis, 2005. 58(4): p:195-207; PMID 16116250
15. Chirkova TV, Naykhin AN, Petukhova GD, Korenkov DA, Donina SA, Mironov AN, Rudenko LG. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol 2011. 18(10): p:1710-8; PMID 21813657; http://dx.doi.org/10.1128/CVI.05116-11
16. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006. 80 (23): p 11756-66; PMID 16971435; http://dx.doi.org/10.1128/JVI.01460-06
17. Hoft DF, Babusis E, Worku S, Spencer CT, Lotten-bach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011. 204(6): p 845-53; PMID 21846636; http://dx.doi.org/10.1093/infdis/ jir436
18. Rudenko L, van den Bosch H, Kiseleva I, Mironov A, Naikhin A, Larionova N, Bushmenkov D. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine, 2011.29 Suppl 1: p A40-4; PMID 21684428; http://dx.doi.org/10.1016/j.vaccine.2011.04.122
19. Rudenk, LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993. 168(4): p 881-7; PMID 8376833; http://dx.doi.org/10.1093/infdis/168.4.881
20. Gustin KM, Maines TR, Belser JA, van Hoeven N, Lu X, Dong L, Isakova-Sivak I, Chen LM, Voeten JT, Heldens JG, et al. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vac- cines in ferrets. J Infect Dis 2011. 204(10): p 1491-9; PMID 21957153; http://dx.doi.org/10.1093/infdis/ jir596
21. Barria MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013. 207(1): p 115-24; PMID 23087433; http://dx.doi.org/10.1093/infdis/jis641
22. Petukhova G, Naikhin A, Chirkova T, Donina S, Korenkov D, Rudenko L. Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal- associated lymphoid tissue (NALT) separation method. Vaccine, 2009. 27(19): p 2580-7; PMID 19428864; http://dx.doi.org/10.1016/j.vaccine.2009.02.035
23. Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014. 209 (12): p 1860-9; PMID 24604819; http://dx.doi.org/10.1093/infdis/jiu123
24. Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 2014. 32(50): p 6798-804; PMID 25446831; http://dx.doi.org/10.1016/j.vaccine.2014.09.070
25. Rudenko L, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, Isakova-Sivak I, Rudenko L, Ross TM. Clinical Testing of Pre-pandemic Live Attenuated A/H5N2 Influenza Candidate Vaccine in Adult Volunteers: Results from a Placebo-controlled, Randomized Double-Blind Phase I Study.
26. WHO, WHO Manual on animal influenza diagnosis and surveillance. Available from: http://www.bvsde.paho.org/bvsacd/cd52/animal.pdf accessed 12 August 2013.2002
27. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999. 37(4): p 937-43; PMID 10074505
28. Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, et al. Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo-Controlled, Randomized Double-Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine. PLoS One 2014.9(2): p e87962; PMID 24533064; http://dx.doi.org/10.1371/journal.pone.0087962
29. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. Avidity of immunoglobulin G directed against human cytomegalovirus during pri- mary and secondary infections in immunocompetent and immunocompromised subjects. Clin Diagn Lab Immunol 1997. 4(4): p 469-73; PMID 9220166
30. He XS, Sasaki S, Narvaez CF, Zhang C, Liu H, Woo JC, Kemble GW, Dekker CL, Davis MM, Greenberg HB. Plasmablast-derived polyclonal antibody response after influenza vaccination. J Immunol Methods 2011. 365(1-2): p 67-75; PMID 21182843; http://dx.doi.org/10.1016/j.jim.2010.12.008
31. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009. 41 (4): p 1149-60; PMID 19897823; http://dx.doi.org/10.3758/BRM.41.4.1149
32. Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzh-off A. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008. 359 (15): p 1631-3; PMID 18843132; http://dx.doi.org/10.1056/NEJMc0805274
33. Rudenko LG, Arden NH, Grigorieva E, Naychin A, Rekstin A, Klimov AI, Donina S, Desheva J, Holman RC, DeGuzman A, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2000. 19(2-3): p 308-18; PMID 10930686; http://dx.doi.org/10.1016/S0264-410X(00)00153-5
34. Zverev VV, Katlinskiı AV, Kostinov MP, Zhirova SN, Erofeeva MK, Stukova MA, Korovkin SA, Mel’nikov SIa, Semchenko AV, Mironov AN. [Comparative clinical trial of vaccines against avian influenza]. Zh Mikrobiol Epidemiol Immunobiol 2007(3): p 10-6; PMID 17672124
35. Chang HS, Sack DA, Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lympho- cytes. Clin Diagn Lab Immunol 2001. 8(3): p 482-8; PMID 11329444
36. Rekha RS, Kamal SM, Andersen P, Rahim Z, Hoq MI, Ara G, Andersson J, Sack D, Raqib R. Validation of the ALS assay in adult patients with culture confirmed pulmonary tuberculosis. PLoS One 2011. 6(1): p e16425; PMID 21283655; http://dx.doi.org/10.1371/journal.pone.0016425
37. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81(1): p 215-28; PMID 17050593; http://dx.doi.org/10.1128/JVI.01957-06
38. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008. 3(8): p e2975; PMID 18714352; http://dx.doi.org/10.1371/journal.pone.0002975
39. Sasaki S, Holmes TH, Albrecht RA, Garcıa-Sastre A, Dekker CL, He XS, Greenberg HB. Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis 2014. 210(6): p 865-74; PMID 24676204; http://dx.doi.org/10.1093/infdis/jiu190
40. Naikhin AN, Chirkova TV, Petukhova GD, Koren’kov DA, Donina SA, Rudenko LG. [Stimulation of homo-and heterologic T-cell immunological memory in volunteers inoculated with live influenza A (H5N2) reassortant vaccine]. Vopr Virusol 2012; 57(1): p 38-42; PMID 22624472